Abstract：
BACKGROUND:Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TNF-alpha biologic secukinumab (fully human IL-17A-inhibitor) vs adalimumab (TNF-alpha-inhibitor) in the treatment of AS in Finland. MATERIALS AND METHODS:In this model-based budget impact analysis, patients were treated either with secukinumab (150 mg) or adalimumab (40 mg). The number of patients and market share of different biologics were based on national reimbursement registry data. Adalimumab was the most commonly used biologic treatment for AS, and in the base case analysis all adalimumab patients are assumed to switch to secukinumab. Response rates were based on a matching-adjusted indirect comparison between secukinumab and adalimumab. Patients not achieving response were switched to another biologic treatment. RESULTS:Treating AS patients with secukinumab instead of adalimumab leads to potential savings of 18.2 million euros within a 5-year time period. The total costs within the follow-up time were 59.5 million euros and 77.7 million euros with and without secukinumab, respectively. According to sensitivity analyses, a higher adoption rate of secukinumab corresponds to higher potential savings. CONCLUSIONS:Secukinumab is a cost-saving treatment option compared with adalimumab in the treatment of AS in Finland. More patients could be treated with a biologic by allocating resources more efficiently.
journal_name
J Med Econjournal_title
Journal of medical economicsauthors
Purmonen T,Törmälehto S,Wahlman H,Puolakka Kdoi
10.1080/13696998.2018.1551227subject
Has Abstractpub_date
2019-02-01 00:00:00pages
151-157issue
2eissn
1369-6998issn
1941-837Xjournal_volume
22pub_type
杂志文章abstract：OBJECTIVE:A cost analysis of once-daily insulin glargine versus three-times daily insulin lispro in combination with oral antidiabetic drugs (OADs) for insulin-naive type 2 diabetes patients in Germany based on the APOLLO trial (A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantu...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990902949614
更新日期：2009-06-01 00:00:00
abstract：OBJECTIVE:To evaluate the cost-effectiveness of biphasic insulin lispro mix 75/25 (LM75/25) and mix 50/50 (LM50/50) compared with a long-acting analog insulin (LAAI) regimen from the perspective of a US healthcare payer. METHODS:A published computer simulation model of diabetes was used to evaluate the cost-effectiven...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.675890
更新日期：2012-01-01 00:00:00
abstract：OBJECTIVE:The relationship between chronic noncancer pain (CNCP) control and pain medication (analgesic) adherence has not been widely documented. The primary aim of this study was to evaluate the relationship between pain intensity and the degree of adherence to analgesic medication prescribed in pain clinics. There w...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2011.598202
更新日期：2011-01-01 00:00:00
abstract：OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1571500
更新日期：2019-04-01 00:00:00
abstract：INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1032974
更新日期：2015-01-01 00:00:00
abstract：:Objective: To estimate the cost-effectiveness of utidelone plus capecitabine therapy compared to capecitabine alone in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes treatment in the Chinese context and provide a reference for the marketing of utidelone in China. Methods: A Markov...
journal_title：Journal of medical economics
pub_type： 杂志文章,随机对照试验
doi：10.1080/13696998.2019.1588125
更新日期：2019-06-01 00:00:00
abstract：OBJECTIVES:To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective. METHODS:A 5-year Markov cohort model was developed. Costs were obtained from the literature and utiliti...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990903562861
更新日期：2010-03-01 00:00:00
abstract：OBJECTIVES:To determine the cost effectiveness of sevelamer vs calcium carbonate in patients with chronic kidney disease and not on dialysis (CKD-ND) from the perspective of the National Health Service (NHS) in the UK. METHODS:A Markov decision analytic model was developed to estimate (1) total life years (LYs), quali...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2013.792267
更新日期：2013-01-01 00:00:00
abstract：AIM:Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2017.1357564
更新日期：2017-10-01 00:00:00
abstract：:Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors afatinib or erlotinib as first-line treatment.Materials and methods: This retrospective analysis used data from three large ad...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1645681
更新日期：2020-01-01 00:00:00
abstract：OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2018.1551226
更新日期：2018-11-21 00:00:00
abstract：:Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1754229
更新日期：2020-08-01 00:00:00
abstract：AIMS:The study compared all-cause and major depressive disorder (MDD)-related healthcare resource use (HRU) and costs in patients with MDD treated with atypical antipsychotic (AAP) adjunctive therapy early or later in treatment. MATERIALS AND METHODS:Adults with MDD and antidepressant treatment (ADT) who newly initiat...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2018.1484373
更新日期：2018-09-01 00:00:00
abstract：OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990903347172
更新日期：2009-01-01 00:00:00
abstract：OBJECTIVE:This study evaluated the overall burden of illness of chemotherapy-induced nausea and vomiting (CINV) and associated all-cause costs from a hospital's perspective (costs to the hospital) in patients with cancer treated with chemotherapy (CT) in the US hospital outpatient setting. METHODS:Patients with a canc...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2010.547237
更新日期：2011-01-01 00:00:00
abstract：OBJECTIVE:Iso-osmolar Iodixanol is associated with a lower rate of contrast-induced acute kidney injury (CI-AKI) in patients at increased risk compared to low-osmolar contrast media (LOCM). The aim of this study was to assess the financial consequences of CI-AKI risk reduction in patients undergoing coronary angiograph...
journal_title：Journal of medical economics
pub_type： 杂志文章,meta分析,评审
doi：10.3111/13696998.2015.1105809
更新日期：2016-01-01 00:00:00
abstract：PURPOSE:To evaluate the insulin wastage and associated acquisition costs when switching from individual patient supply (IPS) of 3-mL pens of rapid-acting insulin (RAI) aspart to floor stock (FS) dispensing of 3-mL vials of RAI lispro, and with conversion from IPS of 3-mL pens to centralized unit dose (CUD) of 10-mL via...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2017.1288126
更新日期：2017-05-01 00:00:00
abstract：INTRODUCTION:SURGIFLO and FLOSEAL are absorbable gelatin-based products that form hemostatic matrices. These products are indicated as adjuncts to hemostasis when control of bleeding by conventional surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. This study analyzed the effect o...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1044994
更新日期：2015-01-01 00:00:00
abstract：OBJECTIVES:This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. METHODS:Data were extracted from the Spanish Ministry of Health records via a claims database containing patient records from 192 private and ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1840180
更新日期：2020-11-02 00:00:00
abstract：OBJECTIVE:To quantify the health economic impact of managing cow milk allergy (CMA) in South Africa, from the perspective of healthcare insurers in both the private and public sectors and parents/carers of CMA sufferers. METHODS:A decision model depicting the management of CMA in South Africa was constructed, using in...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2010.482904
更新日期：2010-01-01 00:00:00
abstract：OBJECTIVE:Allergic rhinitis (AR) is a chronic disease with a substantial clinical and economic burden. This study estimated the potential budget impact (BI) associated with market entry of Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use ('5...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1061533
更新日期：2015-01-01 00:00:00
abstract：:Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1688821
更新日期：2020-03-01 00:00:00
abstract：:Objectives: To describe the clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer (mCRPC) in Chinese patients. Methods: This retrospective study identified a group of patients with newly-developed mCRPC from 2012 to 2016 to extract information fr...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1600524
更新日期：2019-08-01 00:00:00
abstract：:Aims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA for chronic migraine using new utility estimates in an existing model structure.Methods: A previously published model was revised to...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1675417
更新日期：2020-01-01 00:00:00
abstract：OBJECTIVE:To quantify and compare hospital length of stay (LOS) and costs between hospitalized non-valvular atrial fibrillation (NVAF) patients treated with either apixaban or warfarin via a large claims database. METHODS:Adult patients hospitalized with AF were selected from the Premier Perspective Claims Database (0...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2016.1171774
更新日期：2016-08-01 00:00:00
abstract：:Background: Procedural efficiencies can contribute to cost reductions in transcatheter aortic valve replacement procedures (TAVR). The objective of this study is to determine operating room (OR) variable cost per minute in endovascular TAVR procedures, in a real-world hospital setting. Methods: Using Premier data from...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2019.1627364
更新日期：2019-10-01 00:00:00
abstract：OBJECTIVE:The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective. METHODS:To this aim, a retrospective multicentre study was designed analysing admission records from patients admitted with...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1834402
更新日期：2020-10-21 00:00:00
abstract：OBJECTIVE:To compare rates of severe relapse and total direct and indirect costs over a 2-year period between US-based employees with multiple sclerosis (MS) who were adherent and non-adherent to disease-modifying drugs (DMDs). METHODS:Employees with ≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim between ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.667027
更新日期：2012-01-01 00:00:00
abstract：OBJECTIVE:Reduction in health-related quality of life is common in children born small for gestational age (SGA) or children with growth hormone deficiency (GHD). Growth hormone treatment with somatropin in these children leads to normalisation of height. The aim of this study was to determine whether somatropin is a c...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696991003652248
更新日期：2010-03-01 00:00:00
abstract：OBJECTIVE:To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls. METHODS:Patients aged ≥18 years with continuous medical and pharmacy ben...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2013.860375
更新日期：2014-02-01 00:00:00
